These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16873597)

  • 1. Antihypertensive agents in patients with diabetes: trade-off between renal and cardiovascular protection.
    Navaneethan SD; Querques M; Bonifati C; Strippoli GF
    Diabetes Educ; 2006; 32(4):596-602. PubMed ID: 16873597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R; Tonolo G
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
    Abbott KC; Bakris GL
    Prog Brain Res; 2002; 139():289-98. PubMed ID: 12436944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC; Atkins RC
    Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
    Chantrel F; Bouiller M; Kolb I; Hannedouche T
    Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
    Deferrari G; Ravera M; Deferrari L; Vettoretti S; Ratto E; Parodi D
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S224-9. PubMed ID: 12466318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
    Sica DA; Bakris GL
    J Clin Hypertens (Greenwich); 2002; 4(1):52-7. PubMed ID: 11821641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
    Lee GS
    Ann Acad Med Singap; 2005 Jan; 34(1):24-30. PubMed ID: 15726216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
    McKenna K; Thompson C
    Scott Med J; 1997 Aug; 42(4):99-104. PubMed ID: 9507584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus.
    Marshall SM
    Diabet Med; 1999 May; 16(5):358-72. PubMed ID: 10342335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.